<DOC>
	<DOC>NCT01043380</DOC>
	<brief_summary>The purpose of this study was to evaluate the difference in the effect of coronary plaque regression (as measured by intravascular ultrasound [IVUS] imaging) between cholesterol absorption inhibitor and cholesterol synthesis inhibitor.</brief_summary>
	<brief_title>Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Signed written informed consent, 30 to 85 years old, Plan to undergo PCI and LDLC &gt;= 100 mg/dL Familial hypercholesterolemia Being treated with Zetia (Ezetimibe) Being treated with Fibrates Renal insufficiency (serum creatinine &gt;= 2.0 mg/dl) Altered hepatic function (serum aspartate aminotransferase or alanine aminotransferase &gt;= 3folds of standard value in each institute) Undergoing hemodialysis or peritoneal dialysis Allergic to Lipitor and/or Zetia Severe underlying disease Lack of decisionmaking capacity Recognized as inadequate by attending doctor</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Heart Diseases</keyword>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Atorvastatin</keyword>
	<keyword>Ezetimibe</keyword>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Dyslipidemias</keyword>
	<keyword>Intravascular Ultrasound</keyword>
</DOC>